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Abstract: 26 
Fibroproliferative diseases affect a significant proportion of the world’s population. Despite this, 27 
core mechanisms driving organ fibrosis of diverse etiologies remain ill defined. Recent studies 28 
suggest integrin-alpha V serves as a master driver of fibrosis in multiple organs. Although diverse 29 
mechanisms contribute to the progression of fibrosis, TGF-β and IL-13 have emerged as central 30 
mediators of fibrosis during type 1/type 17, and type 2 polarized inflammatory responses, 31 
respectively. To investigate if integrin-alpha V interactions or signaling is critical to the 32 
development of type 2 fibrosis, we analyzed fibroblast-specific integrin-alpha V knockout mice in 33 
three type 2-driven inflammatory disease models. While we confirmed a role for integrin-alpha V 34 
in type 17-associated fibrosis, integrin-alpha V was not critical to the development of type 2-35 
driven fibrosis. Additionally, our studies support a novel mechanism through which fibroblasts, via 36 
integrin-alpha V expression, are capable of regulating immune polarization. We show that when 37 
integrin-alpha V is deleted on fibroblasts, initiation of type 17 inflammation is inhibited leading to 38 
a deregulation of type 2 inflammation. This mechanism is most evident in a model of severe 39 
asthma, which is characterized by a mixed type 2/type 17 inflammatory response. Together, these 40 
findings suggest dual targeting of integrin-alpha V and type 2 pathways may be needed to 41 
ameliorate fibrosis and prevent rebound of opposing pro-fibrotic and inflammatory mechanisms.  42 
 43 
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Introduction: 46 
Progressive tissue fibrosis is one of the leading causes of morbidity and mortality worldwide. 47 
Despite this, there are few effective approaches to treat fibroproliferative diseases, and currently, 48 
the only option for some end stage fibrotic diseases is organ transplantation. Transforming growth 49 
factor-β (TGF-β) is a potent family of cytokines with pleotropic effects, including the ability to 50 
influence T cell differentiation, suppresses inflammatory responses by acting on various 51 
leukocytes, and to induce fibrosis through the activation of collagen producing myofibroblasts (1). 52 
Direct targeting of TGF-β systemically is not generally viewed as therapeutically viable due to off 53 
target effects; therefore, the upstream and downstream mediators that control TGF-β activation 54 
and function have been studied intensively for their potential in anti-fibrotic therapies (2-4). 55 
Integrins are one such upstream target, with accumulating evidence suggesting they may serve as 56 
a therapeutic target to ameliorate collagen deposition in fibrotic diseases. During wound repair, 57 
integrins expressed by both resident cells and cells migrating towards chemoattractants released 58 
at the site of tissue injury can bind to and shear active TGF-β from the latency associated peptide 59 
through the contraction of actin-myosin stress fibers (5, 6). Integrins exist as cell surface 60 
heterodimers, composed of one alpha and one beta subunit that are able to bind to and interact 61 
with the extracellular matrix (7). Of the potential alpha subunits, only alpha V integrin (Itgav) has 62 
been shown to be critical for binding and activating TGF-β (5, 8). Variation within the beta subunit 63 
of the integrin dimer, by contrast, confers tissue specificity (9). Studies targeting Itgav on 64 
myofibroblasts have identified Itgav as a core molecular pathway regulating fibrosis in CCl4-driven 65 
liver fibrosis, bleomycin-induced lung fibrosis, unilateral ureter obstruction-induced kidney 66 
fibrosis, and cardiac and skeletal muscle fibrosis, models largely driven by type 17 immune 67 
responses (10, 11). These studies identified integrin-mediated TGF-β activation as a promising 68 
target for fibroproliferative disease; hence, drugs targeting Itgav are in development.  69 
 70 
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We and others have previously shown that type 2 immunity, characterized by the effector 71 
cytokines IL-4, IL-5, IL-9, and IL-13, can induce fibrosis through TGF-β-dependent and independent 72 
mechanisms (12-14). Nevertheless, the role of integrins in the development of fibrosis during a 73 
more polarized type 2 cytokine driven inflammatory response is largely uncharacterized. 74 
Therefore, we tested the role of Itgav in several Th2-driven murine models of fibrosis including 75 
infection with the helminth Schistosoma mansoni, an S. mansoni egg-induced pulmonary 76 
granuloma model, and a model of severe asthma characterized by mixed type 2/type 17 77 
inflammation (15). We found that in the presence of a strong type 2 fibrotic stimulus, deletion of 78 
Itgav had no effect on collagen deposition, suggesting the role of Itgav in fibrosis is limited to type 79 
17-driven disease entities. Beyond the role of Itgav in fibrosis, we observed marked alterations in 80 
type 2 and type 17 inflammation, suggesting a novel mechanism through which stromal cells are 81 
capable of shaping the local inflammatory milieu. Specifically, we show that Itgav on fibroblasts is 82 
important for the induction of type 17 inflammation. When Itgav is depleted on fibroblasts, type 83 
17 inflammation is significantly reduced, leading to a marked increase in type 2 inflammation. 84 
These findings have important therapeutic implications as they suggest Itgav targeting alone will 85 
not impact fibrosis associated with type 2 inflammation, and may in some conditions exacerbate 86 
these pathologies. 87 
 88 
Results: 89 
Fibroblast-specific Itgav deletion is not universally protective in models of liver fibrosis  90 
To study the role of Itgav on fibroblasts in a type 2 inflammatory setting we utilized 91 
Pdgfrbcre/wtItgavflox/flox(Pdgfrb-cre+) and Itgavflox/flox(Pdgfrb-cre-) mice previously characterized (11). 92 
Platelet derived growth factor receptor beta (Pdgfrb) is specifically expressed at high levels by 93 
both activated and quiescent fibroblasts, making Pdgfrb-cre a useful tool to target deletion of 94 
Itgav specifically to fibroblast populations. To investigate the role of Itgav in type 2-driven liver 95 
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fibrosis Pdgfrb-cre+ and Pdgfrb-cre- littermates were infected with S. mansoni percutaneously via 96 
the tail with 35 cercariae (Figure 1A). Livers from these mice were harvested and analyzed at 12 97 
weeks post infection following establishment of chronic disease with substantial fibrosis. Fibrosis 98 
was unchanged in Pdgfrb-cre+ when compared to Pdgfrb-cre- as observed by gross picrosirius red 99 
staining (PSR), quantification of PSR staining, hydroxyproline content, as well as expression of 100 
collagen associated genes Col3a1 and Col6a1 (Figures 1B-E).  101 
 102 
Previous studies used CCl4-driven liver fibrosis, a type 17-/TGF-β-driven liver fibrosis model, to 103 
demonstrate the critical role of fibroblast-specific Itgav in the development of fibrosis (11, 16). To 104 
reconfirm the role of Itgav in type 17-driven liver disease Pdgfrb-cre+ and Pdgfrb-cre- littermates 105 
were injected intraperitoneally with 1 μL per gram body weight CCl4 twice weekly for 6 weeks 106 
(Figure 1F). We confirmed that Pdgfrb-cre+ mice showed a dramatic reduction in fibrosis as 107 
observed through PSR staining, PSR quantification, hydroxyproline quantification, and Col1a1 and 108 
Col3a1 expression (Figures 1G-J) when compared to Pdgfrb-cre- littermates receiving the same 109 
treatment. These data suggest that in the liver, type 2-driven fibrosis bypasses the pro-fibrotic 110 
mechanisms of Itgav and that this mechanism may be specific to type 17-driven disease insults.  111 
 112 
Fibroblast-specific Itgav deletion is not protective in models of type 2-driven lung fibrosis  113 
To determine the broader applicability of these results to other organ systems, we utilized an 114 
established secondary pulmonary granuloma model that produces a type 2-driven lung disease 115 
similar to that seen in the liver during S. mansoni infection. Pdgfrb-cre+ and Pdgfrb-cre- littermates 116 
were sensitized intraperitoneally with 5,000 S. mansoni eggs and then challenged 14 days later 117 
intravenously with 5,000 live S. mansoni eggs by tail injection, which leads to deposition of eggs in 118 
the pulmonary capillary bed. Lungs were harvested 7 days post challenge at the peak of the 119 
inflammatory response (Figure 2A). Itgav deletion on fibroblasts resulted in no differences in 120 
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granulomatous lung fibrosis, as measured by PSR staining, hydroxyproline content, and Col3a1 121 
and Col6a1 mRNA expression in the lung tissue (Figures 2B-D).  122 
 123 
We next confirmed the importance of Itgav in type 17/ TGF-β -driven fibrosis in the lung using the 124 
bleomycin lung injury model (17). To do so, Pdgfrb-cre+ and Pdgfrb-cre- littermates were 125 
administered 1.5 U/kg of bleomycin intranasally, and their lungs were harvested 28 days post 126 
challenge (Figure 2F). Fibrosis was significantly reduced in the Pdgfrb-cre+ animals as observed by 127 
PSR staining and hydroxyproline content (Figures 2G, 2H). These results expand our findings in the 128 
liver (Figure 1) to the lung, showing that Itgav is critical to type 17-driven fibrosis but is bypassed 129 
in type 2-driven disease models.  130 
 131 
Itgav deletion on fibroblasts causes alterations in immune polarization in both the lung and liver 132 
Fibroblast-specific Itgav has previously been shown to drive fibrosis through TGF-β activation. In 133 
addition to its role in fibrosis, TGF-β is a potent immunoregulatory cytokine and an important 134 
differentiation factor for Th17 cells. Therefore, immunophenotypic analysis was performed to 135 
determine if fibroblasts, via expression of Itgav, regulate the local inflammatory milieu. Pdgfrb-136 
cre+ and Pdgfrb-cre- littermates were infected with S. mansoni and immune responses were 137 
characterized 12 weeks post-infection in the liver (Figure 3A). Liver leukocytes were collected and 138 
re-stimulated ex-vivo for analysis by intracellular cytokine staining and flow cytometry. The 139 
frequency of IL-17A and IL-13 producing CD4+ T cells were not significantly altered in Pdgfrb-cre+ 140 
compared Pdgfrb-cre- mice (Figure 3B). We also assessed cellular determinants associated with 141 
type 2 and type 17 inflammation, namely tissue eosinophil and neutrophil accumulation, 142 
respectively. We did not detect any significant differences in liver neutrophils between the Pdgfrb-143 
cre+ and Pdgfrb-cre- animals. However, in mice lacking Itgav on fibroblasts, eosinophil 144 
accumulation was significantly increased (Figure 3B).  145 
 7 
 146 
We also performed immune characterization in lungs from animals subjected to the secondary 147 
pulmonary granuloma model (Figure 3C). The frequency of IL-13 producing CD4+ T cells was not 148 
significantly altered in the Pdgfrb-cre+ compared to Pdgfrb-cre- mice. However, the frequency of 149 
IL-17A-producing CD4+ T cells was significantly reduced in the Pdgfrb-cre+ compared to Pdgfrb-cre- 150 
animals (Figure 3D). While we did not detect significant differences in lung neutrophils between 151 
the Pdgfrb-cre+ and Pdgfrb-cre- animals, overall frequencies were decreased relative to naïve 152 
animals due to the overwhelming induction of type 2 inflammation in this response (of CD4+ 153 
population: 23.54% TH2 vs 0.81% TH17). However, in mice lacking Itgav on fibroblasts, eosinophil 154 
accumulation was again significantly increased (Figure 3D). Together, these findings (Figure 3A-D) 155 
suggest fibroblast-specific Itgav alters local inflammation in type 2-driven liver and lung disease. 156 
 157 
To expand these findings to type 17-driven models, the CCl4 liver fibrosis model was utilized 158 
(Figure 3E). Analysis of the inflammatory readouts in this model demonstrated a reduction in IL-159 
17A-producing CD4+ T cells in Pdgfrb-cre+ animals, and a concomitant increase in IL-13-producing 160 
CD4+ T cells. We did not observe changes in neutrophil or eosinophil cell frequencies (Figure 3F). 161 
 162 
To investigate if Itgav on fibroblasts influences inflammatory character in type 17-driven lung 163 
disease, the bleomycin-induced lung fibrosis model was used (Figure 3G). No significant 164 
differences in the frequency of IL-17A-producing CD4+ T cells from re-stimulated lung leukocytes 165 
were observed. However, the frequency of IL-13 producing CD4+ T cells increased significantly in 166 
Pdgfrb-cre+ animals. Nevertheless, analysis of infiltrating cell populations revealed a reduction in 167 
both Ly6G+ neutrophils and Siglec-F+ eosinophils in the bronchoalveolar lavage (Figure 4H). 168 
 169 
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These data suggest that while presence of Itgav on fibroblasts may not universally impact the 170 
development of fibrosis, it can regulate the balance between type 2 and type 17 inflammation, 171 
which we and others have demonstrated can play a critical role in the lung (18). Additionally, we 172 
determined that the ability of Itgav to alter inflammation is not limited to type 17 models, as 173 
similar inflammatory changes are seen in both type 17 and type 2 disease models. Nevertheless, 174 
given that the bleomycin and CCl4 models of fibrosis do not depend on antigen driven T cell 175 
activation and associated cytokine responses, as seen in other models used here including the 176 
helminth infections, our ability to detect consistent shifts in type-1/type-2 inflammation with 177 
these models may be more difficult to discern.  178 
 179 
 180 
Itgav deletion on fibroblasts inhibits type 17 inflammation and induces a compensatory type 2 181 
response in cGMP/HDM asthma model 182 
To this end, we took advantage of a model of severe asthma driven by intranasal instillation of low 183 
dose house dust mite extract (HDM) combined with the STING ligand cyclic-di-GMP (cGMP). Unlike 184 
the S. mansoni, bleomycin, and CCl4 models, this model has high levels of type 2/type 17 mixed 185 
inflammation, making it ideal to investigate the inflammatory changes observed when Itgav is 186 
deleted on fibroblasts (15). Pdgfrb-cre+ and Pdgfrb-cre- littermates were sensitized with HDM and 187 
cGMP and subsequently challenged with HDM and a lower dose of cGMP (Figure 4A). While we 188 
did not detect any differences in fibrosis measured by hydroxyproline between Pdgfrb-cre+ and 189 
Pdgfrb-cre- animals (Figure 4B), the type 17 response was significantly decreased in Pdgfrb-cre+ 190 
animals as assessed by the frequency of IL-17A-producing CD4+ T cells in the lung as well as total 191 
tissue IL-17A expression (Figures 4C, 4D). To determine if this corresponded with a functional 192 
decrease in the IL-17A pathway, we assessed lung expression of the IL-17A responsive neutrophil 193 
chemoattractant genes Cxcl1 and Cxcl5, and observed significant reductions in both (Figure 4E). 194 
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Additional analysis of infiltrating tissue and BAL cell populations demonstrated significantly fewer 195 
tissue and BAL neutrophils in Pdgfrb-cre+ animals in agreement with the decreased expression of 196 
the neutrophil chemoattractants (Figure 4F).  197 
 198 
We next asked if the impaired initiation of type 17 inflammation observed in animals with Itgav 199 
deletion on fibroblasts was accompanied by a dysregulation and increased presence of type 2 200 
inflammation as we have previously observed in a chronic HDM model of allergic asthma when 201 
mice were treated with a neutralizing mAb to IL-17A (18). Indeed, compared with Pdgfrb-cre- 202 
animals, Pdgfrb-cre+ mice exhibited an increase in type 2 inflammatory markers as measured by 203 
significant increases in IL-13+ CD4+ T cells isolated from lung tissue of the cGMP/HDM mice as well 204 
as total tissue Il13 expression (Figures 4G, 4H). The increased IL-13 response also correlated with 205 
increased eosinophil accumulation in both lung tissue and BAL (Figure 4I), increased expression of 206 
the eosinophil chemoattractant Ccl11 and the type 2 immune marker Chi3l3. Additionally, IL-13-207 
induced mucus-associated genes, Muc5ac and Gob5 were increased in the lung tissue of Pdgfrb-208 
cre+ animals (19-21) (Figure 4J). Mucus production was also increased, as assessed by AB/PAS 209 
tissue staining (Figure 4K). Additionally, through flexiVent analysis, we observed a significant 210 
reduction in lung resistance when Itgav was deleted on fibroblasts, suggesting improved airway 211 
hyperreactivity (AHR) (supplemental figure 1A). These data indicate that fibroblast specific 212 
deletion of Itgav dysregulates the inflammatory environment, favoring type 2 inflammation, 213 
reducing airway resistance but ultimately resulting in worsening of disease-associated eosinophilia 214 
and mucus production. The observed reduction in the type 17-signature accompanied by 215 
increased type 2-inflammation and mucus production reveals a novel, unexpected, yet pleotropic 216 
role for fibroblasts in regulating inflammation, immune balance, and measures of clinically 217 
relevant disease severity. 218 
 219 
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Itgav deletion on fibroblasts in conjunction with IL-13 neutralization inhibits Th17 inflammation 220 
while inhibiting a compensatory Th2 response in cGMP/HDM asthma model 221 
In order to better understand the mechanism underlying fibroblast processing of TGF-β through 222 
Itgav and its regulation of the immune response, we asked how Pdgfrb-cre+ animals would behave 223 
if the rebound type 2 inflammation was blocked using an IL-13-specific antibody in the same 224 
cGMP/HDM model of severe asthma. Pdgfrb-cre+ and Pdgfrb-cre- littermates were treated with 225 
either anti-IL-13 or an IgG isotype control twice weekly (Figure 5A). No changes in fibrosis between 226 
the Pdgfrb-cre+ and Pdgfrb-cre- animals were observed, and anti-IL-13 treatment did not 227 
significantly affect fibrosis as shown by hydroxyproline quantification (Figure 5B). We observed 228 
the same trend of decreased type 17 inflammation in Pdgfrb-cre+ animals as seen in previous 229 
experiments (Figure 4), with anti-IL-13 antibody treatment having minimal effect on the type 17 230 
signature as assessed by total tissue Il17a expression, frequency of IL-17A-producing CD4+ T-cells 231 
in the lung, total tissue and BAL neutrophil quantification, and expression of neutrophil 232 
chemoattractants Cxcl1 and Cxcl5 (Figures 5C-F).  233 
 234 
We next assessed what effect anti-IL-13 treatment would have on the rebound type 2 235 
inflammatory response seen in Pdgfrb-cre+ animals in the previous experiments (Figure 4). Again, 236 
we observed that the type 2-signature was significantly increased in the absence of Itgav. 237 
However, IL-13 antibody treatment ablated this compensatory increase in Pdgfrb-cre+ mice as 238 
measured by total tissue Il13 expression, frequencies of IL-13+ CD4+ T-cells, total lung tissue and 239 
BAL eosinophil frequency, the eosinophil chemoattractant Ccl11, and the mucus-associated gene 240 
Muc5ac (Figures 5G-I). The increased mucus production in Pdgfrb-cre+ animals receiving 241 
cGMP/HDM treatment was also reduced in anti-IL-13 treated animals (Figure 5J). Together, these 242 
data reveal an important role for fibroblast-specific Itgav expression in the coordination and 243 
regulation of type 17 and type 2–driven inflammatory responses.  244 
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Discussion: 246 
Recent publications have shown Itgav to be part of a fundamental pathway regulating fibrosis in 247 
the liver, lung, skin, kidney, and cardiac and skeletal muscle (9). Blockade of either Itgav or one of 248 
its five beta subunits, via genetic deletion or chemical blockade, substantially attenuated fibrosis 249 
(9, 11). In these studies, Itgav blockade was efficacious both prophylactically and therapeutically. 250 
However, these previous studies did not explore the importance of Itgav in settings where type 2 251 
cytokines are believed to function as important drivers of disease progression. In this study, we 252 
compared mice with or without Itgav on fibroblasts and observed that type 2 fibrosis driven by S. 253 
mansoni infection or egg-induced granuloma formation is independent of fibroblast-specific Itgav 254 
expression in the liver and the lung, respectively. In these type 2-driven disease models, integrin 255 
activation of TGF-β by fibroblasts played little to no detectable role in fibrosis. Nevertheless, we 256 
confirmed that fibrosis driven predominantly by type-17/TGF-β, including bleomycin- and CCl4-257 
driven fibrosis, were highly Itgav dependent (17).  258 
 259 
Unexpectedly, however, we discovered that Itgav deficiency on fibroblasts resulted in a 260 
substantial decrease in type 17 inflammation and corresponding increase in type 2 inflammation, 261 
particularly when a mixed type 17/type 2 inflammatory response was observed. The shift from 262 
type 17/neutrophilic to type 2/eosinophilic inflammation was most striking in the cGMP/HDM 263 
model of severe asthma, which was characterized as mixed type 17/type 2 inflammatory reaction 264 
(15). Similarly, a recent publication by Choy et al. showed that Th2 and Th17 inflammatory 265 
pathways are reciprocally regulated in both murine and human asthmatic lungs characterized by 266 
infiltration of their associated cellular determinants eosinophils and neutrophils, respectively. The 267 
results presented here suggest that the balance of these inflammatory pathways can be regulated, 268 
in part, by fibroblast-specific Itgav expression. Robust regulation of type-17 inflammatory readouts 269 
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mediated by Itgav or Itgb8 expression on dendritic cells has been described previously in EAE as 270 
well as several asthma models, and was associated with significantly reduced AHR (22-24). 271 
However, there were no reported changes in mucus or neutrophil and eosinophil counts despite a 272 
near complete inhibition of Th17 development. Surprisingly, despite less dramatic reductions in 273 
Th17 differentiation, fibroblast deletion of Itgav resulted in similar reductions in AHR as the Itgb8 274 
deletion on dendritic cells that was previously reported. Similarly, global blockade of avb8 with a 275 
neutralizing antibody was shown to inhibit IL-17, BAL neutrophils and AHR in a smoke inhalation 276 
model; although, it is unclear whether these effects were mediated via dendritic cells, fibroblasts, 277 
or both (25).  Additional studies by Kitamura et al. demonstrated fibroblast deletion of Itgb8 278 
resulted in decreased lung neutrophils and Th17 differentiation in response to adenoviral IL-1b 279 
and reduced inflammation and mucus in an ovalbumin challenge lung model that was not 280 
associated with decreased IL-17 or changes in neutrophils (26). AHR was not measured in those 281 
experiments and it is unclear if the additional modulation of the type-2 response, downstream 282 
cellular determinants and mucus we report are specific to the disease model or are mediated thru 283 
an alternate beta integrin. Taken together these data suggest some potential similarities in 284 
mechanisms regulating type-17 inflammation employed by dendritic cells and fibroblasts via 285 
integrins, but they are also suggestive of important differences in cell specific roles that may 286 
depend on Itgav pairing partners and disease context.   287 
 288 
This immune regulation by fibroblasts via Itgav appears to be similar as was recently described for 289 
dendritic cells (23, 24). Our data demonstrate a role for fibroblasts regulating not only the 290 
intensity but also the balance of inflammatory pathways through integrin expression, expanding 291 
on a previous study invoking an Itgb8-mediated role for lung fibroblasts in the induction of 292 
inflammation in response to IL-1β (26). The inflammatory changes detected in Pdgfrb-cre+ mice 293 
may be the result of reduced Th17 induction and a compensatory induction and deregulation of 294 
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the type 2 response. Furthermore, TGF-β is known to support the differentiation of Th0 cells into 295 
Th17 cells and regulatory T cells (27-29). Therefore, the reduction of a major source of active TGF-296 
β through Itgav deletion on fibroblasts may impair Th17 differentiation and license these cells 297 
towards other lineages. These findings posit a novel role for fibroblasts in the immune polarization 298 
decision-making process through Itgav expression. 299 
 300 
These findings also have important therapeutic implications as they suggest targeting Itgav may 301 
inadvertently skew inflammatory responses towards type 2 inflammation and alternative pro-302 
fibrotic mechanisms, particularly when stimuli promoting these alternative pathways are also 303 
present. Previous studies by our group demonstrated that dual blockade of IL-13 and IL-17A in 304 
preclinical asthma models is more efficacious because it limits the rebound inflammation that 305 
occurs during mono-therapy. Similarly, in the cGMP/HDM model used in this current study, 306 
increased type 2 responses in the absence of fibroblast-specific Itgav led to increased eosinophilia 307 
and mucus production, key functional contributors to severe asthmatic disease (30-34). Our 308 
flexiVent data demonstrate that targeting Itgav on fibroblasts decreases airway resistance in the 309 
cGMP/HDM severe asthma model.  This agrees with some reports that neutrophils, not eosinophils, 310 
may be the critical drivers of AHR (35-39). Nevertheless, despite the improvements in AHR, 311 
concomitant upregulation of type 2 immune responses resulted in significant eosinophilia and 312 
mucus production. Mucus hypersecretion is a hallmark of chronic airway diseases, including 313 
asthma, chronic obstructive pulmonary disease, and cystic fibrosis. Studies examining the effect of 314 
mucus on lung pathology show that mucus overproduction is directly correlated to progressive 315 
declines in lung function, worsened quality of life, hospitalizations, and mortality (40-56). 316 
Therefore, we believe that while AHR may be decreased, the induction of mucus overproduction is 317 
of clinical importance and should be considered during treatment and clinical trial development. 318 
Overall, these results indicate that while fibroblast-specific expression of Itgav is a critical driver of 319 
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Th17 inflammation in the asthmatic lung, therapeutic targeting of Itgav may require a coordinated 320 
treatment strategy to prevent compensatory rebound type 2 inflammation. Increasing evidence 321 
suggests that the emergent type 17 inflammation in treatment-resistant severe asthma may be 322 
associated with potent corticosteroid control of the type 2 response (18, 57, 58). The effectiveness 323 
of Itgav deletion on fibroblasts to control Th17 induction indicates it may serve as an ideal paired 324 
therapy with standard therapy or novel blockers of type 2 inflammation. Indeed, in our studies, 325 
administration of anti-IL-13 to animals lacking Itgav on fibroblasts reduced eosinophilia and mucus 326 
production to levels of saline controls. These data suggest that dual blockade of Itgav and IL-13, or 327 
other mediators of type 2 immunity may represent a more efficacious therapeutic strategy for 328 
treatment-resistant asthmatics. 329 
 330 
We conclude that in fibrotic diseases of diverse etiologies, the role of fibroblast-specific Itgav in 331 
fibrosis is highly dependent on the inflammatory stimuli driving the response. In addition, these 332 
data reveal a new role for Itgav expression on stromal cells, as they show it plays a critical role in 333 
shaping the character of local inflammatory responses. Thus, while targeting Itgav in fibrotic 334 
disease may be efficacious in some settings, it will be important to understand the inflammatory 335 
mechanisms driving the fibrogenic response in order to better predict clinical outcome. Our 336 
findings suggest Itgav inhibition may be utilized to attenuate type 17 inflammation in diseases 337 
such as severe asthma. While type-17 inflammatory pathways may be downregulated by Itgav 338 
blockade, the potential for an undesirable augmentation of type-2 inflammation and resulting 339 
pathology should be monitored carefully. Indeed, in settings where there is high risk of 340 
compensatory type 2 inflammation, dual blockade strategies may be required to maximize 341 
therapeutic benefit.  342 
 343 
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Materials and Methods: 352 
Mice  353 
Pdgfrbcre/wtItgavflox/flox were obtained from Neil Henderson (11); animals used in studies were age 354 
and gender matched, littermates and between 6-8 weeks of age. Mice were terminally 355 
anesthetized with sodium pentobarbital. All animals were housed under specific pathogen-free 356 
conditions at the National Institutes of Health in an American Association for the Accreditation of 357 
Laboratory Animal Care-approved facility.  358 
 359 
Schistosoma mansoni Infection 360 
Mice were infected percutaneously by suspending tails in pond water containing 35 S. mansoni 361 
cercariae for 45 minutes. Cercariae were obtained by shedding infected Biomphalaria glabrata 362 
snails (Biomedical Research Institute).  363 
 364 
Pulmonary Granuloma Model 365 
S. mansoni eggs were extracted from the livers of infected mice (Biomedical Research Institute, 366 
Rockville, MD, USA). For the induction of secondary lung granulomas, mice were sensitized 367 
intraperitoneally (i.p.) with 5,000 S. mansoni eggs and then challenged 14 days later with 5,000 368 
live S. mansoni eggs i.v.  369 
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 370 
CCl4 and Bleomycin Fibrosis Models 371 
For chronic CCl4–induced liver fibrosis, mice were injected i.p. with 1 μl CCl4 (Sigma)/gram body 372 
weight or olive oil twice a week for 6 weeks. To induce pulmonary fibrosis, mice were 373 
anesthetized, and saline or with 1.5 U bleomycin (Sigma)/kg body weight was instilled 374 
intratracheally.  375 
 376 
cGMP/HDM Model of Severe Asthma  377 
Mice were sensitized to 25 μg HDM (greer labs) extract and 5 μg cyclic-di-GMP (cayman chemical 378 
company) delivered intranasally on days 1, 3, and 5. Mice were rested 5 days, then intranasally 379 
administered with 3 challenge sets consisting of 3 consecutive daily challenges with HDM and 380 
cyclic-di-GMP with 4 days of rest between each set. Each challenge set included 0.5 μg cyclic-di-381 
GMP with 25 μg HDM on day 1, then 25 μg HDM on the following 2 days.  382 
 383 
Histopathology 384 
Murine liver and lung lobes were harvested and fixed with Bouin’s-Hollande solution. Fixed tissue 385 
was embedded in paraffin for sectioning, and stained (Histopath of America, Clinton, MD) with 386 
Wright’s Giemsa, Picrosirius red (PSR), or Alcian Blue Periodic Acid Schiff (AB/PAS).  387 
 388 
Fibrosis Quantification 389 
Cross sections of three liver lobes from each mouse were stained with PSR and imaged under 390 
polarized light. Granuloma volume was obtained by measuring the length (a) and width (b) of 391 
granulomas with a single visible egg. Values obtained were entered into the formula of a spheroid 392 
(
4
3
𝜋𝑎𝑏2). 393 
 394 
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IL-13 Neutralization 395 
For antibody therapy, 250 μg of anti–IL-13 (Genentech clone 262A-5-1), or control Ab (BioXCell 396 
clone MOPC-21, catalog #BE0083) was injected intraperitoneally twice weekly. 397 
 398 
Hydroxyproline Assay 399 
Mouse liver tissue (200 mg) or the left lower lung lobe incubated overnight at 110 °C in 6M HCl. 400 
Hydroxyproline content was measured using a colorimetric chloramine T assay (59). 401 
 402 
Cell Isolation and Flow Cytometry 403 
Approximately 400 mg of liver or lung tissue was diced and incubated in 100 U/ml of collagenase 404 
(Sigma) at 37°C for an hour with rocking. Tissue was then passed through a 70-μm nylon filter to 405 
obtain a single cell suspension. Leukocytes were isolated on a 40% Percoll (Sigma) gradient, and 406 
treated with ACK lysis buffer to remove erythrocytes. Isolated cells were either immediately 407 
stained for cellular analysis or stimulated with phorbol 12-myristate 13-acetate (10ng/ml) and 408 
ionomycin (1 μg/ml) in the presence of Brefeldin A (10 μg/ml) for three hours and fixed. Cells were 409 
permeabilized (Cytofix/Cytoperm buffer; BD Biosciences; San Diego, CA) and stained for 30 410 
minutes with fluorescently labelled antibodies purchased from eBioscience (Waltham, MA) 411 
include the following: CD45(30-F11; 1:250) and IL-13(eBio13A; 1:150). Antibodies purchased from 412 
Biolegend (San Diego, CA) include the following: CD16/CD32 (93; 1:500), CD11b (M1/70; 1:250), 413 
and IL-17A(TC11-18H10.1; 1:150). Antibodies purchased from BD Pharmingen (Billerica, MA) 414 
include the following: CD4 (RM4-5; 1:150), Ly6C (AL-21; 1:250), ly6G(1A8; 1:350), and Siglec-F 415 
(E50-2440; 1:275). Cells were collected on an LSR II flow cytometer equipped with FACSDIVA (BD 416 
Biosciences) software and data were analyzed with FlowJo software (Tree Star, Ashland, OR).  417 
 418 
Murine Gene Expression Analyses 419 
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Liver and lung tissue was homogenized in TRIzol Reagent (Life Technologies; Grand Island, NY) 420 
with a Precellys 24 (Bertin Technologies; Montigny-le-Bretonneux, France). Total RNA was 421 
extracted with chloroform using a MagMax-96 Total RNA Isolation Kit (Qiagen), and reverse 422 
transcribed to cDNA using SuperScript II Reverse Transcriptase (Life Technologies). Gene 423 
expression was quantified using Power SYBR Green PCR Master Mix (Applied Biosystems) by RT-424 
PCR on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Gene expression is 425 
described relative to RPLP2 mRNA levels in naïve liver and lung tissue. 426 
Gene Forward Sequence 5' - 3' Reverse sequence 5'-3' 
Ccl11 GAATCACCAACAACAGATGCAC ATCCTGGACCCACTTCTTCTT 
Chil3 CATGAGCAAGACTTGCGTGAC GGTCCAAACTTCCATCCTCCA 
Col3a1 AACCTGGTTTCTTCTCACCCTTC ACTCATAGGACTGACCAAGGTGG 
Col6a1 CGCCCTTCCCACTGACAA GCGTTCCCTTTAAGACAGTTGAG 
Cxcl1 CTGGGATTCACCTCAAGAAC GAAGCCAGCGTTCACCAGAC 
Cxcl5 TGCGTTGTGTTTGCTTAACCG AGCTATGACTTCCACCGTAGG 
Gob5 AGGAAAACCCCAAGCAGTG GCACCGACGAACTTGATTTT 
Il13 CCTCTGACCCTTAAGGAGCTTAT CGTTGCACAGGGGAGTCTT 
Il17a TTTAACTCCCTTGGCGCAAAA CTTTCCCTCCGCATTGACAC 
Muc5ac CAGGACTCTCTGAAATCGTACCA AAGGCTCGTACCACAGGGA 
 427 
Statistical Analysis 428 
Experimental groups were randomized and researchers were blinded to the groups. Prism 7 was 429 
used to compute statistical analyses. Data was tested for normal distribution and two-tailed 430 
Welch’s t test or one-way ANOVA were used to determine statistical significance. A p value <0.05 431 
was deemed statistically significant. 432 
 433 
Ethics 434 
The National Institute of Allergy and Infectious Diseases Division of Intramural Research Animal 435 
Care and Use Program, as part of the National Institutes of Health Intramural Research Program, 436 
approved all of the experimental procedures (protocol “LPD 16E”). The program complies with all 437 
applicable provisions of the Animal Welfare Act 438 
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(www.aphis.usda.gov/animal_welfare/downloads/awa/awa.pdf) and other federal statutes and 439 
regulations relating to animals.  440 
 20 
Figure 1. Fibroblast-specific Itgav deletion is not universally protective in models of liver fibrosis 441 
 (A) Pdgfrbcre/wtItgavflox/flox(Pdgfrb-cre+) and Itgavflox/flox(Pdgfrb-cre-) mice were infected with 442 
Schistosoma Mansoni percutaneously via the tail with 25–35 cercariae. Livers were harvested 12 443 
weeks post infection. (B) 5-μm sections of paraffin-embedded liver tissue were stained with PSR. 444 
(C) Quantification of positive PSR staining, expressed as percentage of pixels positive for stain. 445 
From left to right: n = 4, 4, 9, 6. (D) Liver collagen deposition, expressed as micromoles of 446 
hydroxyproline per gram of liver. From left to right: n = 4, 4, 9, 6. (E) RNA was extracted from liver 447 
tissue, with Col3a1, and Col6a1 quantified by quantitative RT-PCR. From left to right: n = 4, 4, 8, 6. 448 
(F) Pdgfrb-cre+ and Pdgfrb-cre- mice were injected i.p. with 1μl per gram body weight CCl4 twice 449 
weekly for 6 weeks. (G) 5-μm sections of paraffin-embedded liver tissue were stained with PSR. 450 
(H) Quantification of positive PSR staining, expressed as percentage of pixels positive for stain. 451 
From left to right: n = 5, 9, 10. (I) Liver collagen deposition, expressed as micromoles of 452 
hydroxyproline per liver. From left to right: n = 4, 5, 14, 15. (J) RNA was extracted from lung tissue, 453 
with Col1a1 and Col3a1mRNA quantified by quantitative RT-PCR. From left to right: n = 3, 3, 9, 10. 454 
Data representative of two replicate experiments; all scale bars represent 100 μm; ∗p < 0.05, ∗∗p 455 
< 0.01, ∗∗∗p < 0.001.  456 
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Figure 2. Fibroblast-specific Itgav deletion is not protective in models of type 2-driven lung 457 
fibrosis  458 
(A) Pdgfrb-cre+ and Pdgfrb-cre- mice were sensitized intraperitoneally with 5,000 S. mansoni eggs 459 
and then challenged 14 days later intravenously with 5,000 live S. mansoni eggs. Lungs were 460 
harvested 7 days post challenge. (B) 5-μm sections of paraffin-embedded lung tissue were stained 461 
with PSR. (C) Pulmonary collagen deposition, expressed as micromoles of hydroxyproline per lung. 462 
From left to right: n = 4, 4, 9, 15. (D) Quantification of granuloma volume. From left to right: n = 4, 463 
4, 4, 4. (E) RNA was extracted from lung tissue, with Col3a1, and Col6a1 quantified by quantitative 464 
RT-PCR. From left to right: n = 3, 3, 4, 6. (F) Pdgfrbcre/wtItgavflox/flox(Pdgfrb-cre+) and 465 
Itgavflox/flox(Pdgfrb-cre-) mice were administered 1.5U bleomycin i.n. and lungs were harvested 28 466 
days later. (G) 5-μm sections of paraffin-embedded lung tissue were stained with picrosirius red. 467 
(H) Pulmonary collagen deposition, expressed as micromoles of hydroxyproline per lung. From left 468 
to right: n = 6, 6, 12, 9. 469 
Data representative of two replicate experiments; all scale bars represent 100 μm; ∗p < 0.05, ∗∗p 470 
< 0.01, ∗∗∗p < 0.001.  471 
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Figure 3. Itgav deletion on fibroblasts causes alterations in immune polarization in both the lung 472 
and liver 473 
(A) Pdgfrbcre/wtItgavflox/flox(Pdgfrb-cre+) and Itgavflox/flox(Pdgfrb-cre-) mice were infected with 474 
Schistosoma Mansoni percutaneously via the tail with 25–35 cercariae. Livers were harvested 12 475 
weeks post infection (B) Liver lymphocytes were collected from S. Mansoni infected animals and 476 
re-stimulated ex-vivo for analysis by intracellular staining for IL-13, IL-17A, Ly6G, and Siglec-F and 477 
analyzed via flow cytometry. From left to right: n = 4, 4, 8, 6. (C) Pdgfrb-cre+ and Pdgfrb-cre- mice 478 
were sensitized intraperitoneally with 5,000 S. mansoni eggs and then challenged 14 days later 479 
intravenously with 5,000 live S. mansoni eggs. Lungs were harvested 7 days post challenge. (D) 480 
Lung lymphocytes were collected from mice, subjected to secondary lung granuloma, model and 481 
re-stimulated ex-vivo for analysis by intracellular staining for IL-13, IL-17A, Ly6G, and Siglec-F and 482 
analyzed via flow cytometry. From left to right: n = 5, 4, 9, 14. (E) Pdgfrb-cre+ and Pdgfrb-cre- mice 483 
were injected i.p. with 1μl per gram body weight CCl4 twice weekly for 6 weeks. (F) Liver 484 
lymphocytes were collected and re-stimulated ex-vivo for analysis by intracellular staining for IL-485 
17A, IL-13, Ly6G, and Siglec-F and analyzed via flow cytometry. From left to right: n = 4, 5, 4. (G) 486 
Pdgfrbcre/wtItgavflox/flox(Pdgfrb-cre+) and Itgavflox/flox(Pdgfrb-cre-) mice were administered 1.5U 487 
bleomycin i.n. and lungs were harvested 28 days later. (H) Lung lymphocytes were collected and 488 
re-stimulated ex-vivo for analysis by intracellular staining for IL-17A, IL-13, Ly6G, and Siglec-F and 489 
analyzed via flow cytometry. From left to right: n = 3, 5, 14, 10.  490 
Data representative of two replicate experiments; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001   491 
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Figure 4. Itgav deletion on fibroblasts inhibits Th17 inflammation and induces a compensatory 492 
Th2 response in cGMP/HDM asthma model 493 
(A) Pdgfrbcre/wtItgavflox/flox(Pdgfrb-cre+) and Itgavflox/flox(Pdgfrb-cre-) mice were sensitized with 494 
house dust mite allergen and ci-di-GMP and subsequently challenged with HDM and a lower dose 495 
of ci-di-GMP. (B) Pulmonary collagen deposition, expressed as micromoles of hydroxyproline per 496 
lung. From left to right: n = 6, 7, 12, 13. (C) Lung lymphocytes were collected and re-stimulated ex-497 
vivo for analysis by intracellular staining for IL-17A. From left to right: n = 5, 6, 12, 12. (D-E) RNA 498 
was extracted from lung tissue, with Il17a, Cxcl1 and Cxcl5 mRNA quantified by quantitative RT-499 
PCR. From left to right: n = 5, 6, 11, 12. (F-G) Lung lymphocytes were collected and re-stimulated 500 
ex-vivo for analysis by intracellular staining for Ly6G, and IL-13 and analyzed via flow cytometry. 501 
From left to right: n = 6, 7, 10, 12. (H) RNA was extracted from lung tissue, with Il13 mRNA 502 
quantified by quantitative RT-PCR. From left to right: n = 4, 4, 5, 5. (I) Lung lymphocytes were 503 
collected and re-stimulated ex-vivo for analysis by intracellular staining for Siglec-F and analyzed 504 
via flow cytometry. From left to right: n = 6, 7, 10, 12. (J) RNA was extracted from lung tissue, with 505 
Ccl11, Chil3, Muc5ac and Gob5 mRNA quantified by quantitative RT-PCR. From left to right: n = 5, 506 
6, 11, 12. (K) 5-μm sections of paraffin-embedded lung tissue were stained with AB/ PAS. Data 507 
representative of two replicate experiments; all scale bars represent 100 μm; ∗p < 0.05, ∗∗p < 508 
0.01, ∗∗∗p < 0.001.  509 
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Figure 5 Itgav deletion on fibroblasts in conjunction with IL-13-neutralization inhibits Th17 510 
inflammation while inhibiting a compensatory Th2 response in cGMP/HDM asthma model 511 
(A Pdgfrbcre/wtItgavflox/flox(Pdgfrb-cre+) and Itgavflox/flox(Pdgfrb-cre-) mice were sensitized with house 512 
dust mite allergen and ci-di-GMP and subsequently challenged with HDM and a lower dose of ci-513 
di-GMP. 250ug of anti-IL-13 was also administered twice weekly. (B) Pulmonary collagen 514 
deposition, expressed as micromoles of hydroxyproline per lung. From left to right: n = 6, 6, 11, 515 
11, 14, 13. (C) RNA was extracted from lung tissue, with Il17a mRNA quantified by quantitative RT-516 
PCR. From left to right: n = 6, 4, 8, 8, 14, 12. (D-E) Lung lymphocytes were collected and re-517 
stimulated ex-vivo for analysis by intracellular staining for IL-17A and Ly6G. From left to right: n = 518 
5, 3, 10, 9, 14, 12. (F-G) RNA was extracted from lung tissue, with Cxcl1, Cxcl5, and Il13 mRNA 519 
quantified by quantitative RT-PCR. From left to right: n = 6, 4, 8, 8, 14, 12. (H) Lung lymphocytes 520 
were collected and re-stimulated ex-vivo for analysis by intracellular staining for IL-13 and Siglec-F 521 
and analyzed via flow cytometry. From left to right: n = 6, 4, 8, 8, 14, 12. (I) RNA was extracted 522 
from lung tissue, with Ccl11 and Muc5ac mRNA quantified by quantitative RT-PCR. From left to 523 
right: n = 6, 4, 8, 8, 14, 12. (J) 5-μm sections of paraffin-embedded lung tissue were stained with 524 
AB/PAS. Data representative of two replicate experiments; all scale bars represent 100 μm; ∗p < 525 
0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.  526 
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